齐拉西酮治疗老年期首发精神分裂症的对照研究  

Clinical study of ziprasidone in the treatment of naive senile schizophrenia

作　　者：郑友玲 

机构地区：[1]徐州市东方人民医院,江苏徐州221004

出　　处：《中国民康医学》2011年第23期2949-2950,共2页Medical Journal of Chinese People’s Health

摘　　要：目的:比较齐拉西酮和氟哌啶醇治疗首发老年期精神分裂症的疗效和安全性。方法:将60例老年期首发精神分裂症患者随机分成齐拉西酮与氟哌啶醇治疗组,疗程8周,采用阳性与阴性症状量表(PANSS)评定疗效,以治疗中出现的症状量表(TESS)评定不良反应。结果:两组疗效无显著差异,齐拉西酮不良反应较氟哌啶醇更少。结论:齐拉西酮治疗老年期首发精神分裂症疗效好,安全性高,有利于长期巩固治疗。Objective：To compare the efficacy and safety between ziprasidone and haloperidol in the treatment of naive senile schizophrenia. Methods： Sixty naive senile schizophrenia were randomly divided into zipresidone group or haloperidol group for 8 weeks. The positive negative syndrome scale （PANSS） and treatment emergent symptom scale （TESS） were used to assess the efficacy and the side effects. Results： there was no significant difference in the chnical efficacy between ziprasidone and haloperidol treatment. The efficacy of zipresidone were lower than the efficacy of haloperidol. Conclusions ： ziprasidone has a good efficacy and high safety in the treatment of naive senile schizophrenia, which is favorable for long - term maintain treatment.

关 键 词：齐拉西酮 老年期 精神分裂症 氟哌啶醇 

分 类 号：R749.3[医药卫生—神经病学与精神病学]